ライフサイエンスコーパス: dose

1 P < 0.01 vs. controls, P < 0.05 vs. standard-dose).

2 kin of tangerine fed animals despite a lower dose.

3 influenza vaccination consisting of a single dose.

4 scular delivery of a two-fold higher vaccine dose.

5 red a 6-month maintenance period on the same dose.

6 independent cells and lowers cumulative drug dose.

7 extended beyond 70 days following the final dose.

8 isit [FUV] 1) and 3 (FUV2) weeks after final dose.

9 elium ion irradiation with a well-controlled dose.

10 increase in titer following a second vaccine dose.

11 e association study of usual daily methadone dose.

12 be used to identify the optimum radiotherapy dose.

13 pharmacodynamically active at well-tolerated doses.

14 CT scans were obtained every 24 h throughout dosing.

15 al cholesterol levels in rats following oral dosing.

16 ocompatible, via the nasal route, on chronic dosing.

17 ingle morning doses versus twice-daily split dosing.

18 cks of six) to receive either two intranasal doses (0.25 mL per nostril) of LAIV H5N2 (101 participan

19 as noted in all the vaccine recipients after dose 1.

20 m to receive inotuzumab ozogamicin (starting dose 1.8 mg/m(2) per cycle [0.8 mg/m(2) on day 1; 0.5 mg

21 cible protein 10 (IP-10) were measured after doses 1 and 8, then 1 (follow-up visit [FUV] 1) and 3 (F

22 On the tenth day following initiation of dosing, 10 patients underwent an intensive pharmacokinet

23 ine component peaked at day 35 (7 days after dose 2).

24 ndently increased this value in the standard-dose (27.9 +/- 9 nmol x min(-1) x g(-1), P < 0.05 vs. co

25 2q4), IAI 2 mg every 8 weeks after 5 monthly doses (2q8), or macular laser photocoagulation.

26 Fish treated with higher dietary Se doses (32.5 and 57.5 mug Se/g) exhibited impaired perfor

27 c immune response approximately 28 days post-dose 4, measured by gpELISA (estimated geometric mean fo

28 xposure comparable with that of the standard dose (5 mg twice daily) in patients with preserved renal

29 Although repelling at high doses, 6-MHO/GA mixtures were not active at the levels e

30 Infection with low-dose A/X31 H3N2 led to prolonged deterioration of lung f

31 2, but remains low; variability of radiation dose according to facility continues to be wide.

32 The need for dose adjustment and the incidence of torsades de pointes

33 Fractional-dose administration of inactivated poliovirus vaccine (f

34 showed increased CCR5 expression after high-dose allergen exposure while CXCR4, CXCR5, CCR6, and CCR

35 We studied 1039645 recipients of high-dose and 1683264 recipients of standard-dose vaccines du

36 vaccines during 2012-2013, and 1508176 high-dose and 1877327 standard-dose recipients during 2013-20

37 In regression models, APOE-e4 dose and age both consistently increased risk, as did lo

38 ab tesirine, including the maximum tolerated dose and dose-limiting toxic effects.

39 We aimed to establish the maximum tolerated dose and establish the recommended phase 2 dose of velip

40 e beam configurations and variations in peak dose and irradiated area in the response of normal tissu

41 therefore, an urgent need to develop single-dose and long-lasting rabies vaccines.

42 breast harder or firmer [p=0.002 for reduced-dose and p<0.0001 for partial-breast]) compared with who

43 -inferiority can be claimed for both reduced-dose and partial-breast radiotherapy, and was confirmed

44 The unlabeled drug dose and plasma concentration leading to a 50% reduction

45 Estimated total body clearance normalized by dose and weight was lower in the Eld group compared with

46 ow eyes (n = 207) were treated with 5-minute dosing and considered in the safety analysis.

47 er function, basic immune markers, treatment dose, and tumor morphology.

48 immunization regimen (dose, interval between doses, and drug partner), this vaccine could be used for

49 t the signaling duration and across Tgf-beta doses, and significantly increased the information trans

50 erates all of these cellular phenotypes in a dose- and age-dependent manner in cortex and striatum of

51 Dose- and time-dependent tumor uptake was studied in nud

52 concurrently with an antiplatelet drug (low-dose aspirin and a VKA: 3.6% of cases and 1.1% of contro

53 ormed a cohort study of 601 527 users of low-dose aspirin for primary or secondary prevention in the

54 s (CIs) for cancer-specific mortality by low-dose aspirin use after adjusting for potential confounde

55 ropomorphic phantoms for estimation of organ dose at computed tomography (CT).

56 e goal of giving the right drug at the right dose at the right time.

57 After 4 doses at weekly intervals, the survival period of the mi

58 and anatomic outcomes compared with monthly dosing at 1 year.

59 aphylaxis in C57BL/6 mice upon repeated i.p. dosing because of an anti-idiotypic anti-drug Ab immune

60 nivariate analysis, age >60 years, radiation dose, bilateral ocular involvement at presentation, and

61 d limited protection from a single antenatal dose, but revaccinating mothers during every pregnancy d

62 Although whole gut irradiation with these doses caused lethal GI syndrome, focal (5 mm) radiation

63 alan should thus be considered standard high-dose chemotherapy and ongoing randomised studies will co

64 the 4-week post-treatment period, ascending dose cohorts underwent a further double-blind crossover,

65 tricitabine, and tenofovir alafenamide fixed-dose combination [bictegravir group] and 330 with dolute

66 methoprim-sulfamethoxazole in a single fixed-dose combination tablet), 12 weeks of fluconazole, 5 day

67 Purpose To determine if the use of reduced-dose computed tomography (CT) for evaluation of kidney s

68 Conclusion Use of reduced-radiation dose CT for evaluation of kidney stones has increased si

69 actor, mitoxantrone plus cytarabine, or high-dose cytarabine).

70 Furthermore, low-dose DAC preserved HSPC-NK killing, proliferation, and i

71 More cells were killed by PTX dose-dense-equi than with PTX conventional, but with the

72 Temporal, dose-dependent and specific disruption of the TJ-associa

73 ) and in vivo (using rainbow trout fry) in a dose-dependent and time-dependent manner.

74 tious cycle in hepatoma cells and HFLCs in a dose-dependent and time-dependent manner.

75 Furthermore, there was a dose-dependent association between the prevalence of low

76 more, we observed that 1B6 displayed a rapid dose-dependent clearance (t(1/2) 10-60 h) in contrast to

77 psychoactive component of cannabis, produced dose-dependent conditioned place aversion and a reductio

78 protein kinase (MAPK) cascade and triggers a dose-dependent differentiation response.

79 intracellular Angpt-2 protein in a time- and dose-dependent fashion thereby indirectly reducing the r

80 We found that PEGylation prevented dose-dependent hemolysis in the concentrations studied (

81 SH2 overexpression results in a significant, dose-dependent increase in EGFR tyrosine phosphorylation

82 k of decompensation, mortality, and HCC in a dose-dependent manner (P for trend <0.0001, <0.0001, and

83 Plasma levels of fitusiran increased in a dose-dependent manner and showed no accumulation with re

84 elicase activities are inhibited by Rev in a dose-dependent manner, although ATP-independent helicase

85 ented amphetamine-induced hyperactivity in a dose-dependent manner, similar to the atypical antipsych

86 early initiation of liver regeneration in a dose-dependent manner, without modifying the peak regene

87 Oral leniolisib led to a dose-dependent reduction in PI3K/AKT pathway activity as

88 Patients who received inclisiran had dose-dependent reductions in PCSK9 and LDL cholesterol l

89 lusion A small but statistically significant dose-dependent T1-weighted signal enhancement was observ

90 dministration of ALN-GO1 resulted in potent, dose-dependent, and durable silencing of the mRNA encodi

91 ell-derived factor-1alpha-mediated migration dose-dependently but minimally affected cell viability.

92 tro ADME and pharmacokinetics properties and dose-dependently counteracted acute lung eosinophilia in

93 Doxorubicin selectively and dose-dependently increased this value in the standard-do

94 rcumin improved disease activity index (DAI) dose-dependently, while the anti-inflammatory efficacy o

95 High-dose DHA supplementation in APOE4 carriers before the on

96 olone (FQ) use was defined as receiving >/=5 doses during the first month of treatment.

97 coronary segment interpretability, effective dose (ED), and diagnostic accuracy were assessed at CT a

98 but patients with no chemotherapy still had doses equivalent to five tablets per day of 5-mg hydroco

99 andomized, double-blind, placebo-controlled, dose-escalating study of BMS-936559, including HIV-1-inf

100 Compound 1 was tested in dose escalation studies in rats and dogs and was found t

101 0 and topotecan in 3-week cycles using 3 + 3 dose escalation.

102 dose-length product (DLP), and size-specific dose estimate (SSDE).

103 d minimum (1.25 [1.06-1.47] per kJ/m(2)) UVR dose exposure.

104 and to establish a current average radiation dose for CT evaluation for kidney stones by querying a n

105 1,200 mg to be the recommended single-agent dose for future studies in FL and DLBCL, with 800 mg bei

106 Additionally, radiation absorbed doses for major tissues of human were calculated based o

107 th postprimary (D127) and postbooster (D301) doses for pneumococcal serotypes.

108 Minimizing wastage and use of a 2-dose fractional-IPV schedule could extend IPV immunizati

109 of (11)C-nicotine and the absorbed radiation dose from whole-body (11)C-nicotine PET imaging of 11 he

110 Results Average doses from 647 regimens published during 2010 to 2015 we

111 adult bee/day) at sublethal, field-realistic doses given over 3 days.

112 eing more than 2.03 (p=0.003 for the reduced-dose group and p=0.016 for the partial-breast group, com

113 mg/kg (n = 14) or received a placebo (n = 2/dosing group).

114 NA were similar for the 40-120 mg once-daily dose groups regardless of baseline Gag polymorphisms.

115 articipants received half their standard TKI dose (imatinib 200 mg daily, dasatinib 50 mg daily, or n

116 type 1 (Th1) immune responses, whereas high-dose immunization primes responses characterized by regu

117 .03), above the 90th percentile for the 5-mg dose in patients with preserved renal function.

118 Failure to reduce the dose in patients with severe kidney disease may increase

119 Patient doses in this study was higher compared to previous rese

120 Higher radiation doses increased the redox potential, promoted the lipid

121 5th and 75th (DRL) percentiles for volume CT dose index (CTDIvol), dose-length product (DLP), and siz

122 y due to competing causes of death over this dose interval.These results confirm and extend earlier f

123 ed 5 mg/kg belatacept every 2 weeks, and the dosing interval was extended to 4 weeks after 5 applicat

124 e able to optimize the immunization regimen (dose, interval between doses, and drug partner), this va

125 valent with 2-minute and 5-minute riboflavin dosing intervals at 6 months (0.97 and 0.76 diopters, re

126 Prospective open-label, unilateral single-dose, intravitreal injection of AAV2(Y444,500,730F)-P1ND

127 ypothesis, and its use, in the form of ALARA dosing, is responsible for misguided concerns promoting

128 f 15 to receive placebo (normal saline), low-dose ketamine (0.5 mg/kg), or high dose ketamine (1.0 mg

129 ine), low-dose ketamine (0.5 mg/kg), or high dose ketamine (1.0 mg/kg) after induction of anaesthesia

130 xhibit resistance to 10,000 times the lethal dose (LD50) of BoNT/A, and transfusion of these red bloo

131 centiles for volume CT dose index (CTDIvol), dose-length product (DLP), and size-specific dose estima

132 ose-limiting toxicity analysis set: three at dose level 1 (1 mg/kg), three at dose level 2 (3 mg/kg),

133 t: three at dose level 1 (1 mg/kg), three at dose level 2 (3 mg/kg), six at dose level 3 (10 mg/kg),

134 kg), three at dose level 2 (3 mg/kg), six at dose level 3 (10 mg/kg), and six at dose level 4 (20 mg/

135 , six at dose level 3 (10 mg/kg), and six at dose level 4 (20 mg/kg).

136 t asymptomatic hyponatremia at the 1.0-mg/kg dose level.

137 ion data from 21 patients into six radiation dose levels (12.5%, 25%, 37.5%, 50%, 75%, and 100%) on t

138 ry estimates indicate that the kidney is the dose-limiting organ, with an estimated human absorbed do

139 ced peripheral neuropathy (CIPN) is a common dose-limiting side effect experienced by patients receiv

140 ne, including the maximum tolerated dose and dose-limiting toxic effects.

141 cation to FGF19-driven HCC may be limited by dose-limiting toxicities mediated by FGFR1-3 receptors.

142 18 patients were analysed in the dose-limiting toxicity analysis set: three at dose level

143 Only one patient experienced a dose-limiting toxicity-grade 3 transient asymptomatic hy

144 ivity reactions to ASA, especially following doses lower than 100 mg, should directly undergo desensi

145 culatory-disease mortality radiation risk at doses <0.5 Gy.

146 The "For Presentation" standard-dose mammograms and synthetic images were analyzed by us

147 promise for efficient spectrum imaging, low-dose mapping of beam-sensitive specimens, trace element

148 re few data examining how sorafenib starting dose may influence patient outcomes and costs.

149 ement of fosfomycin in conjunction with high-dose meropenem.

150 oportion of women who received each elagolix dose met the clinical response criteria for the two prim

151 ing full-dose proton-pump inhibitor and high-dose Metronidazole in group A, and full-dose proton-pump

152 In this study, we explore the effect of low dose N-acetyl-L-cysteine therapy, delivered using a targ

153 Discontinuation of low-dose naltrexone resulted in flaring of symptoms, which c

154 Low-dose naltrexone, 3 mg nightly, titrated to 4.5 mg nightl

155 d within 2 to 3 days on rechallenge with low-dose naltrexone.

156 osing regimens through either evidence-based dosing nomograms or preferably through the use of dosing

157 The MTD for dual-dose O6-benzylguanine plus carmustine was also ascertain

158 BC, and 2 UBC) received a single intravenous dose of (68)Ga-NOTA-AE105 (154 +/- 59 MBq; range, 48-208

159 s cerana olfactory learning in larvae (lower dose of 0.033 microg/larvae/day over 6 days) and, in a s

160 and, in a separate experiment, adults (lower dose of 0.066 microg/adult bee/day) at sublethal, field-

161 Single oral dose of 10 mg of dexamethasone (n = 293) or identical pl

162 Escitalopram was given at a dose of 10 mg per day for 3 weeks and 20 mg per day ther

163 o, to receive subcutaneous tocilizumab (at a dose of 162 mg) weekly or every other week, combined wit

164 ting organ, with an estimated human absorbed dose of 2.20E-01 mSv/MBq.

165 2:1 ratio to receive either adalimumab (at a dose of 20 mg or 40 mg, according to body weight) or pla

166 o-controlled food challenges to an eliciting dose of 300 mg or less of peanut protein.

167 e to staff was low; surgeons received a mean dose of 34 +/- 15 muSv per procedure.

168 Patients and Methods We delivered PMRT at a dose of 36.63 Gy in 11 fractions of 3.33 Gy over 11 days

169 d whether rituximab maintenance therapy at a dose of 375 mg per square meter of body-surface area adm

170 ton's tyrosine kinase (BTK), at a once-daily dose of 420 mg achieved BTK active-site occupancy in pat

171 eeks or subcutaneous interferon beta-1a at a dose of 44 mug three times weekly for 96 weeks.

172 A single dose of 5 x 10(12) or 2 x 10(13) genome copies of AMT-06

173 osis to receive intravenous ocrelizumab at a dose of 600 mg every 24 weeks or subcutaneous interferon

174 nazole, 5 days of azithromycin, and a single dose of albendazole, as compared with standard prophylax

175 -mts), starting from 4 hours after 600 mg/kg dose of APAP, resulted in early initiation of liver rege

176 INTERPRETATION: A maximum tolerated dose of CPI-613 was established at 500 mg/m(2) when used

177 ctive at delivering a therapeutically active dose of KAFAK to bovine cartilage explants, suppressing

178 HIGH SFM+ vs LOW SFM+ (CONTROL matched the dose of LOW).

179 ssigned treatment, 207 received at least one dose of MABp1 and 102 at least one dose of placebo.

180 Patients who were taking a stable dose of methotrexate were randomly assigned in a 2:1 rat

181 Ps promotes ethylene capture, and subsequent dose of negative potential (-2.0 V) induces the release.

182 rimary care with acute sore throat, a single dose of oral dexamethasone compared with placebo did not

183 least one dose of MABp1 and 102 at least one dose of placebo.

184 ( 1:1000 dilution) physiologically relevant dose of simulated mixture in air for two weeks in separa

185 assigned patients who received at least one dose of study drug during the maintenance period were in

186 All patients who received at least one dose of study drug were included in all analyses.

187 ed in all patients who received at least one dose of study treatment.

188 We found that a single dose of tamoxifen less than 10% of the mean dose used fo

189 the identification of the maximum tolerated dose of the combination.

190 d dose and establish the recommended phase 2 dose of veliparib combined with neoadjuvant capecitabine

191 was not identified; the recommended phase 2 dose of venetoclax in combination with rituximab was 400

192 luded all patients who received at least one dose of venetoclax.

193 ine applied once in combination with 2 daily doses of 120 mg/m2 of O6-benzylguanine.

194 to receive either once-daily rivaroxaban (at doses of 20 mg or 10 mg) or 100 mg of aspirin.

195 sen 640 mg intravenously after three loading doses of 640 mg.

196 lts in decreased SOCE, particularly at lower doses of agonists.

197 Three doses of aluminium-absorbed HBsAg were delivered at 0, 1

198 d blood cells are resistant to highly lethal doses of BoNT/A.

199 ardial infarction to placebo or one of three doses of canakinumab (50 mg, 150 mg, or 300 mg) given su

200 l, prednisone, and custirsen received weekly doses of custirsen 640 mg intravenously after three load

201 th through 15 months who received at least 3 doses of diphtheria-tetanus-acellular pertussis vaccine

202 Subjects received single doses of dofetilide, quinidine, ranolazine, and placebo.

203 Immunization with low doses of gp96 primes T helper type 1 (Th1) immune respon

204 mographic Surveillance System to include two doses of HRV with the standard infant vaccines at 6 and

205 hat was enhanced by priming with physiologic doses of IL-5.

206 the low radiation absorption of tumors, high doses of ionizing radiations are often needed during RT,

207 nd randomized trials that compared different doses of naloxone, administration routes, or transport v

208 unoglobulins and two doses, showed that both doses of SCIg IgPro20 were efficacious and well tolerate

209 enables physicians to achieve fast adequate dosing of antibiotics to improve the outcome of patients

210 ed on the presented results, a less frequent dosing of mavacoxib is proposed compared to celecoxib an

211 uble-masked trials reported here, once-daily dosing of netarsudil 0.02% was found to be effective and

212 randomized trial found that treat and extend dosing of ranibizumab 0.3 mg with and without angiograph

213 e research into the medicinal behaviours and dosing of this living antibacterial.

214 ermine the effect of inhalational anesthetic dose on risk of severe postoperative respiratory complic

215 Herein, we assessed the efficacy of steroid dosing on sarcolemmal repair, muscle function, histopath

216 corded similar adverse effects after reduced-dose or partial-breast radiotherapy, including two patie

217 ng adjuvant chemotherapy had modestly higher doses ( P = .002), but patients with no chemotherapy sti

218 After 9 years of timely 3-dose PCV coverage of >92%, all-age IPD in Australia almo

219 +/- 0.2 vs. 3.6 +/- 0.4 percentage injected dose per gram).

220 ratio of mean tumor to bone marrow absorbed dose per unit administered activity of (131)I, after THW

221 To evaluate the single-dose pharmacokinetic bioequivalence of 3 (1 branded and

222 n the study (13 [24%] of 54 enrolled at this dose plus five [11%] of 45 initially administered D who

223 60 h) in contrast to 1F11, which presented a dose-proportional pharmacokinetic profile and a half-lif

224 lues for methylone and MDC were greater than dose-proportional, suggesting non-linear accumulation.

225 Using full-dose proton-pump inhibitor and high-dose Metronidazole i

226 high-dose Metronidazole in group A, and full-dose proton-pump inhibitor and prescription from a Gastr

227 Over the entire dose range, there are negative mortality dose trends for

228 who require or choose active treatment, low-dose rate brachytherapy (LDR) alone, EBRT alone, and/or

229 of Ag dispersal but may also concentrate the dose received by organisms, which subsequently ingest th

230 The mean proportion of routine vaccine doses received by children younger than 24 months of age

231 , and 1508176 high-dose and 1877327 standard-dose recipients during 2013-2014.

232 unting detector (PCD) technology can improve dose-reduced chest computed tomography (CT) image qualit

233 Here, we report that a 0.1 Gy radiation dose reduces cancer progression by deactivating the JAK1

234 Dose reduction through adsorption to aluminium hydroxide

235 disease may increase bleeding risk, whereas dose reductions without a firm indication may decrease t

236 An evidence-based optimised dose regimen was constructed that would provide piperaqu

237 dual patient data on SAEs, assigned drug and dosing regimen, and baseline prognostic factors were req

238 able optimized dosing, the use of customized dosing regimens through either evidence-based dosing nom

239 ion for kidney stones by querying a national dose registry.

240 rces of referral, body region scanned, type, dose, related adverse events and route of administration

241 No apparent temporal or dose-related changes in clinical status (specifically ac

242 in hemodynamic response shows characteristic dose-related effects that differ depending on agonistic

243 The biomarker results revealed multiphasic dose-response curves, which suggested toxicity mechanism

244 data for each country, we estimate a common dose-response function, which we use to compute national

245 85644 may contribute to variation in 25(OH)D dose-response in healthy postmenopausal Caucasian women.

246 d for analyzing multiple-stressor data using dose-response regression.

247 stricted cubic spline models to evaluate the dose-response relationships.

248 hould generate biomarkers useful for in vivo dose responses of beta-lapachone treatment in humans, av

249 cidal antibodies up to 4 years after a three-dose schedule of bivalent rLP2086.

250 o administrations of immunoglobulins and two doses, showed that both doses of SCIg IgPro20 were effic

251 g nomograms or preferably through the use of dosing software supplemented by therapeutic drug monitor

252 However, at this high dose some organoleptic properties were affected.

253 Reduced starting dose sorafenib patients had more Barcelona Clinic Liver

254 e research should focus on optimal probiotic dose, species, and formulation.

255 To assess the effect of high-dose spironolactone and usual care on N-terminal pro-B-t

256 At high doses, staple dissociation increases which causes struct

257 mab (odds ratio = 9.52; P = 0.001), and high-dose steroids (odds ratio = 5.05; P = 0.01) retained sig

258 erance remains widely accepted: the use of a dosing strategy that provides an interval of no or low n

259 were adoptively transferred to multiple low-dose streptozotocin (STZ)-induced T1DM.

260 were injected in right eyes of 14 rats (low dose; study group I, high dose; study group II).

261 es of 14 rats (low dose; study group I, high dose; study group II).

262 -1) x g(-1), P < 0.05 vs. controls) and high-dose subgroups (37.2 +/- 7.8 nmol x min(-1) x g(-1), P <

263 , combination fludarabine-melphalan with low-dose TBI after haplocord stem cell transplant assures go

264 n whole OSPW are acutely toxic at much lower doses than we previously reported for the OSPW-OF (i.e.,

265 The ED05 is the dose that elicits a reaction in 5% of allergic subjects.

266 developed profound RPE and retinal damage at doses that caused minimal effects in wild-type mice, and

267 To enable optimized dosing, the use of customized dosing regimens through ei

268 Delays in dosing time will result in transient periods of lower co

269 Aortic EC were stimulated with low-dose TNFalpha (0.3 ng/ml) in a microfluidic channel that

270 The radiation dose to staff was low; surgeons received a mean dose of

271 ogroup B vaccines and the need for a booster dose to sustain individual protection against invasive m

272 More work is needed to optimize its dosing to minimize adverse events, such as peripheral ne

273 ire dose range, there are negative mortality dose trends for all circulatory disease (p = 0.014) and

274 lind, placebo-controlled, multiple-ascending-dose trial of inclisiran administered as a subcutaneous

275 een age-eligible for HPV vaccination, with 3-dose uptake across age cohorts being about 50%-77%).

276 dose of tamoxifen less than 10% of the mean dose used for recombination induction, caused adverse ef

277 At the 2 x 10(7) PFU dose (used in phase 3 trials), the most common local adv

278 luated the comparative effectiveness of high-dose vaccine in preventing postinfluenza deaths during 2

279 high-dose and 1683264 recipients of standard-dose vaccines during 2012-2013, and 1508176 high-dose an

280 ine was associated with a 4.0% increase in 1-dose varicella vaccine coverage.

281 s alternate days and given as single morning doses versus twice-daily split dosing.

282 oints in the placebo group (P<0.001 for each dose vs. placebo), and everyday-activities scores improv

283 oints in the placebo group (P<0.001 for each dose vs. placebo).

284 Each dose was given for five consecutive days during which se

285 The radiotherapy dose was not associated with DFS when adjusting for the

286 The maximum tolerated dose was not identified; the recommended phase 2 dose of

287 ile up to 20 mg/kg and the maximum tolerated dose was not reached.

288 Sequential reduction of busulfan dose was successfully achieved per study design.

289 th IMT (treated at 100, 165, and 280 mg/m(2)/dose) was 86%.

290 Beam thickness, spacing and incident dose were 100 or 600 microm, 400 or 1200 microm and 360

291 ds of a reduction in the oral glucocorticoid dose were more than 4 times as high with benralizumab as

292 Median change in successfully consumed doses were 0, 43, and 130 mg of protein in the placebo,

293 for different grains at various irradiation doses were compared and revealed efficient defect absorp

294 Heart doses were not associated with overall survival.

295 Differences in organ doses were not related to tube start angles (P = .17).

296 RT plans and cardiac doses were reviewed.

297 to mice for 10 weeks, followed by five oral dosing with purified AHC or ovalbumin on alternate days

298 opically overexpressing KDM5B in response to dosing with TCA cycle metabolite pro-drug esters, sugges

299 Edoxaban (DU-176b) vs. Standard Practice of Dosing With Warfarin in Patients With Atrial Fibrillatio

300 ric analysis demonstrated a (64)Cu effective dose within the acceptable range for clinical PET imagin